



Annual General Meeting

21 December 2020



Board and Key Management Personnel



Diverse skillset to build a track record of executing on advancing the Company's strategic ambitions

Guy Cowan | **Independent Non-Executive Chairman** | Australia

Mr Cowan is a senior company director based in Queensland and was appointed non-executive Chairman and Director on 28 February 2018.

Qi (Christina) Chen | **Non-Executive Director** | China

Ms Chen was appointed a director on 28 July 2017, and has significant experience in branded FMCG, particularly in the Asian region. Ms Chen is also a director of ChaCha Food Co Ltd, a leading company in branded nuts and roasted foods that is listed with market capitalisation of c. USD6 billion

Peter O'Keeffe | **Non-executive Director** | Australia

Peter has had a long history and association with the Company. He is an accountant with significant commercial experience in Australia

Andrew Bond | **Non-executive director** | Australia

Andrew is the immediate past CEO of the Company and brings significant knowledge and insight to the board.

Dennis Lin | **Executive Director** | Strategic Leadership, High Growth Execution in FMCG | Australia

Dennis has been involved with the business since 2016 and has a specific focus on strategically directing above industry growth in key markets such as USA and China through organic growth and acquisition activities.

Lisa Davis | **CFO & Company Secretary** | Finance, Regulatory Compliance, Systems | Australia

Lisa joined the business in early 2019 and has been instrumental in working through the transformation of the business. She is responsible for Finance as well as IT systems.

Online Attendees Question Process

When the Question function is available, the Q&A icon will appear at the top of the app




To send in a question, click in the 'Ask a question' box, type your question and press the send arrow




Your question will be sent immediately for review

✓ Received



Tabling of the Company Financial Statements

Prepared by Buderim Group Limited



Online Attendees Voting Process

When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen




To vote simply select the direction in which you would like to cast your vote. The selected option will change colour

For

Against

Abstain

There is no submit or send button, your selection is automatically recorded. You can change your mind or cancel your vote any time before the poll is closed



330-481-282

i

You have voted on 0 of 2 items

Resolution 1: Adoption of the Remuneration Report

Select a choice to send.

For Against Abstain

CANCEL

Resolution 2: Approval of issue of securities under the Short-Term Incentive Plan

Select a choice to send.

For Against Abstain

CANCEL

Resolution 1: The adoption of Remuneration Report

Resolution 2: The election of Andrew Bond as a Director

Resolution 3: The re-election of Guy Cowan as a Director

Resolution 4: Ratification of prior share issue under Placement

Resolution 5: Change of Company Name

Resolution 6: Appointment of Auditor

Resolution 7: Approval of Enhanced Placement Capacity.

Adoption of the Remuneration Report

“That, for the purpose of Section 250R(2) of the Corporations Act and for all other purposes, the section of the Directors’ Report dealing with the remuneration of the Company’s Directors and senior executives (“Remuneration Report”) is adopted

Vote Type	Voted	% Voted
For	70,386,900	94.82
Against	3,328,998	4.48
Open-Useable	521,664	0.70
Abstained	61,147	
TOTAL	74,298,709	100.00

Election of Andrew Bond as a Director

“That Mr Andrew Bond, who was appointed to the Board to fill a casual vacancy on 1 October 2020 and retires in accordance with clause 15.4 of the Company’s constitution and, being eligible, be elected as a Director of the Company.”

Vote Type	Voted	% Voted
For	71,693,952	95.22
Against	3,083,383	4.09
Open-Useable	521,664	0.69
Abstained	21,993	
TOTAL	75,320,992	100.00

Election of Guy Cowan as a Director

“That Mr Guy Cowan, who was appointed to the Board to fill a casual vacancy on 1 October 2020 and retires in accordance with clause 15.4 of the Company’s constitution and, being eligible, be elected as a Director of the Company.”

Vote Type	Voted	% Voted
For	71,693,786	95.22
Against	3,083,383	4.09
Open-Useable	521,664	0.69
Abstained	22,099	
TOTAL	75,320,932	100.00

Ratification of prior share issue under Placement

“That, pursuant to and in accordance with Listing Rule 7. and for all other purposes, shareholders ratify the prior issue and allotment of 12,903,279 shares at an issue price of \$0.17 to the Allottees as set out in the Explanatory Memorandum.”

Vote Type	Voted	% Voted
For	71,046,162	95.04
Against	3,187,137	4.26
Open-Useable	521,664	0.70
Abstained	71,852	
TOTAL	74,826,815	100.00

Change of Company Name

“That, with effect from the date on which the ASIC alters the details of the Company’s registration, for the purposes of section 157(1) of the Corporations Act and for all other purposes, approval is given for the Company’s name to be changed from “Buderim Group Limited” to “Health and Plant Protein Group Limited” and that for the purposes of section 136(2) of the Corporations Act, the Constitution be amended to reflect the change of the Company’s name by replacing all references to “Buderim Group Limited” with references to “Health and Plant Protein Group Limited””

Vote Type	Voted	% Voted
For	71,361,817	94.83
Against	3,375,175	4.48
Open-Useable	521,664	0.69
Abstained	62,276	
TOTAL	75,320,932	100.00

Appointment of Auditor

“That, pursuant to section 327B of the Corporations Act and for all other purposes, Ernst & Young, having been nominated by a shareholder and having consented in writing to act in the capacity of auditor, be appointment as Auditor of the Company.”

Vote Type	Voted	% Voted
For	71,773,980	95.32
Against	3,003,355	3.99
Open-Useable	521,664	0.69
Abstained	21,933	
TOTAL	75,320,992	100.00

Approval of enhanced placement capacity

“That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, shareholders approve the issue of such a number of shares equal to up to 10% of the issued capital of the Company, at the time of the issue, calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms and conditions in the Explanatory Memorandum.”

Vote Type	Voted	% Voted
For	71,311,928	94.89
Against	3,304,060	4.40
Open-Useable	535,906	0.71
Abstained	169,038	
TOTAL	75,320,932	100.00

ED & Chairman Address



- Consolidated Group Income* \$72.59 m (2019 \$73.86m) despite significant COVID-19 impacts
- Net Loss after Income Tax \$(7.56)m (2019 \$(0.23m))
 - Key Drivers
 - Ginger segment impairment \$6.05m recognised following announcement of sale transaction
 - Macadamia sales in US impacted in second half by COVID-19
 - Tourism operations closed for three months in second half due to COVID-19
- US macadamia business well positioned to benefit from increased focus on health and plant protein
- Early market indications of recovery post COVID-19 evident

Key activities undertaken since Ginger Division Sale




- Comprehensive IT systems review and upgrade to enhance efficiency and cyber security
- Streamlining corporate reporting systems to concentrate on key business initiatives that can enhance shareholder returns
- General review of corporate costs and identifying efficiencies, as well as skillset gaps
- Preparation for the launch of the Company's new corporate name and identity, including a new website.

- Repayment of \$5 million convertible notes
- Reduction of outstanding balance of Greensill Capital working capital finance facility
- Strategic review of Kapua Macadamia Orchard to take place immediately
 - The orchard is one of the largest in the world
 - Macadamia nuts are grown in natural habitat with little irrigation
 - Orchards have one of the lower costs of production
 - Independently assessed to be c. USD32 million

The Company is in one of the strongest position it has ever been in many years, with a robust cash and cash equivalents reserve to grow the business and strategically assess opportunities.

- All of the shares were allotted on 18 December 2020 to raise \$6.2 million (before costs)
- Strong support from existing investors, and new institutional and retail investors
- The proceeds will be applied to working capital, and allow further liquidity for the Company's value proposition to be better reflected in its market capitalisation

Strategic initiatives to become global leader in health and plant protein utilizing macadamia business as a platform business



- The business is continuing to trade in a volatile environment, mainly due to Covid-19 restrictions and limitations
- Our business is less impacted as we operate in mostly grocery and convenience channels (rather than tourist and souvenir channels)
- Further investments in digital channels from e-commerce to content marketing to further build brand awareness
- Recent purchase order from an existing customer that would utilise excess macadamia not extensively used in our retail products, with the order size over AUD5 million over a 12 month period
- The business continues to grow in its category, and has visibility on becoming the no. 1 branded macadamia business in the next 2 years.

Business Overview



Global Player in Health and Plant Protein



Focus on higher margin sustainable business in health and plant protein categories, anchored by macadamia business



Health

All better-for-you products, that promote a healthy lifestyle and provide education and opportunity for proper nutrition



Plant Protein

Plant-based proteins that complements people's diet as the trends and eating habits shift to a more sustainable and holistic approach



HPP

The ultimate parent company that provides healthier plant-based protein products across multiple brands, categories, and touch points for consumers



Question



Resolution 1: The adoption of Remuneration Report

Resolution 2: The election of Andrew Bond as a Director

Resolution 3: The re-election of Guy Cowan as a Director

Resolution 4: Ratification of prior share issue under Placement

Resolution 5: Change of Company Name

Resolution 6: Appointment of Auditor

Resolution 7: Approval of Enhanced Placement Capacity.

Disclaimer

This presentation (Presentation) is dated 21 December 2020 and has been prepared by Buderim Group Limited (ACN 010 978 800) (HPP). The material in this Presentation is general background information about HPP's current at the date of the Presentation. It has been prepared based on information available to it, including information from third parties, and has not been independently verified nor does it purport to be complete. No representation or warranty, express or implied, is made as to the fairness, accuracy or completeness of the information or opinions contained in this Presentation.

This presentation does not constitute investment or financial product advice (nor taxation, accounting or legal advice) and does not take into account the investment objectives, financial situations or needs of any particular investor. It is not a prospectus, product disclosure statement or other disclosure or offering document under Australian law or any other law. This Presentation is not and should not be considered a recommendation to, or offer or an invitation to acquire shares in HPP, nor does not and will not form the basis of any contract of commitment for the acquisition of shares. The distribution of this Presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions.

This Presentation contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of HPP, its directors and management. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indicator or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of HPP's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of the HPP, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward-looking statements are based on information available to HPP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), none of HPP, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward looking statements.

Certain non-IFRS financial information has been included to assist in making appropriate comparisons with period periods to assess the operating performance of the business. HPP uses these measures to assess the performance of the business and believes that the information is useful to investors. Non-IFRS information has not been subject to auditor review.

Unless otherwise stated, all dollar values are in Australian dollars (\$ or A\$). A number of figures, amounts, percentages, estimates, calculations of value and fractions in this Presentation are subject to the effect of rounding.

Contact:

Dennis Lin

Executive Director

E: dlin@buderimgroup.com